Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to -$272000.0.

  • Cardiff Oncology's Change in Receivables fell 26287.43% to -$272000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$365000.0, marking a year-over-year decrease of 18690.48%. This contributed to the annual value of $484000.0 for FY2024, which is 20020.7% up from last year.
  • Latest data reveals that Cardiff Oncology reported Change in Receivables of -$272000.0 as of Q3 2025, which was down 26287.43% from $121000.0 recorded in Q2 2025.
  • Over the past 5 years, Cardiff Oncology's Change in Receivables peaked at $167000.0 during Q3 2024, and registered a low of -$515000.0 during Q2 2023.
  • For the 5-year period, Cardiff Oncology's Change in Receivables averaged around -$3526.3, with its median value being $86000.0 (2021).
  • Per our database at Business Quant, Cardiff Oncology's Change in Receivables surged by 213333.33% in 2021 and then crashed by 59519.23% in 2023.
  • Cardiff Oncology's Change in Receivables (Quarter) stood at $141000.0 in 2021, then fell by 14.18% to $121000.0 in 2022, then dropped by 25.62% to $90000.0 in 2023, then skyrocketed by 71.11% to $154000.0 in 2024, then plummeted by 276.62% to -$272000.0 in 2025.
  • Its Change in Receivables was -$272000.0 in Q3 2025, compared to $121000.0 in Q2 2025 and -$368000.0 in Q1 2025.